HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...

HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment ...

HeartBeam Inc. (NASDAQ:BEAT) saw its stock soar 52.6% in premarket trading Wednesday after the company announced that the FDA ...

HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...

Cleaning materials can also deteriorate the quality of ECG lead wires and result in false alarms on hospital floors, which can increase alarm fatigue among clinical staff. During a May 12 webinar ...

Standard ADC components seldom provide enough flexibility to meet the conflicting needs of today’s medical designs. By Ian ...

The Skeptical Cardiologist has been evaluating a demo version of AliveCor's new KardiaMobile 6L. I have been a huge advocate of Kardia's single-lead ECG and use it with great success in dozens of my ...

The resting electrocardiogram (ECG) furnishes essential information for the diagnosis, management, and prognostic evaluation of patients with congestive heart failure (CHF). Almost any ECG diagnostic ...

Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...